Druggable cancer phosphatases
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Progress has been made in pharmacological targeting of tumor suppressor and oncogenic phosphatases for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serine/threonine phosphatases: mechanism through structure
Shi, Y. (2009) · Cell · doi:10.1016/j.cell.2009.10.006 · Cited by 1,488
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925
The target landscape of clinical kinase drugs
Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854 · cited 1×
“Additional challenges related to kinase inhibitors include lack of specificity among inhibitors targeting structurally very similar active sites across the kinome (10).”
BackgroundCIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
Self-citationResponse and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease
Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., Zampino, G., van der Burgt, I., Palleschi, A., Petrucci, T. C., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/499925 · Cited by 415
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344 · cited 2×
“Importantly, nongenetic and cancer-selective inhibition of PP2A by inhibitor proteins allows PP2A’s tumor suppressor activity to be therapeutically reactivated (4, 21).”
BackgroundSelf-citationRevealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2
Barford, D., & Neel, B. G. (1998) · Structure · doi:10.1016/s0969-2126(98)00027-6 · Cited by 321
Research works printed but not linked: 84
- 10.1016/j.biocel.2017.10.017 · DOI · Paper page
- 10.3892/ijmm.2017.3036 · DOI · Paper page
- 10.1093/jnci/djx232 · DOI
- 10.1038/nrc3298 · DOI · Paper page
- 10.1158/1078-0432.CCR-16-0954 · DOI · Paper page
- 10.1111/febs.14617 · DOI · Paper page
- 10.1016/j.celrep.2014.07.036 · DOI · Paper page
- 10.1038/nmeth.1636 · DOI · Paper page
- 10.1038/s41580-018-0015-0 · DOI · Paper page
- 10.1016/j.biocel.2018.01.005 · DOI · Paper page
- 10.1016/j.biocel.2017.09.013 · DOI
- 10.1016/j.semcdb.2016.01.009 · DOI · Paper page
- 10.1016/j.molcel.2009.02.015 · DOI · Paper page
- 10.1016/j.cell.2020.04.005 · DOI · Paper page
- 10.1016/j.cell.2020.12.020 · DOI · Paper page
- 10.1038/ng1156 · DOI · Paper page
- 10.1038/s41467-018-06823-9 · DOI · Paper page
- 10.1021/jm400474r · DOI · Paper page
- 10.1021/jm901645u · DOI · Paper page
- 10.1016/S0092-8674(00)80938-1 · DOI · Paper page
- 10.1093/neuonc/noz107 · DOI
- 10.1126/sciadv.aay4458 · DOI · Paper page
- 10.1158/0008-5472.CAN-19-3038 · DOI · Paper page
- 10.1021/acschembio.7b00980 · DOI · Paper page
- 10.1038/nm.4497 · DOI · Paper page
- 10.15252/embj.2019103695 · DOI · Paper page
- 10.1042/BST20160161 · DOI · Paper page
- 10.1158/0008-5472.CAN-16-1134 · DOI · Paper page
- 10.1016/j.cell.2020.03.051 · DOI · Paper page
- 10.1158/0008-5472.CAN-08-2760 · DOI · Paper page
- 10.1074/jbc.271.19.11059 · DOI · Paper page
- 10.1126/science.1197048 · DOI · Paper page
- 10.7554/eLife.53003 · DOI
- 10.1016/j.ccell.2020.05.019 · DOI · Paper page
- 10.1016/j.ccr.2005.10.015 · DOI · Paper page
- 10.1016/j.bmc.2015.07.007 · DOI · Paper page
- 10.1016/S0021-9258(17)49933-9 · DOI
- 10.1172/JCI126390 · DOI
- 10.1093/braincomms/fcaa002 · DOI
- 10.1172/JCI68951 · DOI · Paper page
- 10.1158/1078-0432.CCR-13-2575 · DOI · Paper page
- 10.3389/fonc.2015.00021 · DOI · Paper page
- 10.1002/emmm.201201283 · DOI · Paper page
- 10.1177/0091270011427908 · DOI
- 10.1096/fj.201802264R · DOI
- 10.1172/JCI31095 · DOI · Paper page
- 10.1038/s41375-018-0288-5 · DOI
- 10.1016/j.canlet.2019.10.007 · DOI
- M. Swingle, L. Ni, R. E. Honkanen, Small-molecule inhibitors of ser/thr protein phosphatases: Specificity, use and common forms of abuse. Methods Mol. Biol. 365, 23–38 (2007).
- 10.1080/15384047.2015.1040961 · DOI · Paper page
- 10.1158/1535-7163.MCT-17-1143 · DOI
- 10.1038/s41467-018-04425-z · DOI · Paper page
- 10.1038/ncb3376 · DOI
- 10.1038/nchembio.1528 · DOI · Paper page
- 10.1074/jbc.C117.819110 · DOI
- 10.1016/j.jmb.2019.06.008 · DOI
- 10.1038/s41467-019-10127-x · DOI
- 10.1074/jbc.M608940200 · DOI · Paper page
- 10.1038/s41375-020-0937-3 · DOI
- 10.1074/jbc.M115.705863 · DOI
- 10.1172/JCI76614 · DOI
- 10.1039/C6OB00946H · DOI
- 10.18632/oncotarget.23787 · DOI
- 10.1124/jpet.119.262188 · DOI
- 10.1172/jci.insight.87607 · DOI
- 10.1002/cam4.772 · DOI · Paper page
- 10.1158/1078-0432.CCR-03-0771 · DOI · Paper page
- 10.1038/onc.2010.449 · DOI
- 10.1158/0008-5472.CAN-06-2644 · DOI
- 10.1073/pnas.95.6.3014 · DOI · Paper page
- 10.1016/j.ccell.2015.05.008 · DOI · Paper page
- 10.1016/j.canlet.2017.10.007 · DOI
- 10.1056/NEJMoa060096 · DOI · Paper page
- 10.1038/nchembio.190 · DOI · Paper page
- 10.1002/cbic.201402000 · DOI
- 10.1038/nm.4310 · DOI · Paper page
- 10.1124/jpet.116.239756 · DOI
- 10.1038/s41586-020-2513-4 · DOI
- 10.1016/j.cell.2006.11.039 · DOI · Paper page
- 10.1126/science.aau0159 · DOI · Paper page
- 10.1073/pnas.2002964117 · DOI
- 10.1158/1055-9965.EPI-05-0121 · DOI · Paper page
- 10.1158/1541-7786.MCR-14-0018 · DOI
- 10.1158/1078-0432.CCR-12-0053 · DOI · Paper page
Cited by
Laine, A., Nagelli, S. G., Farrington, C., Butt, U., Cvrljevic, A. N., Vainonen, J. P., Feringa, F. M., Grönroos, T. J., Gautam, P., Khan, S., et al. (2020) · doi:10.1101/2020.08.27.269902 · Cited by 54
“Importantly, in our model the enhanced TopBP1/RAD51 chromatinrecruitmentisduetolossofadirectandPP2A-independent CIP2A – TopBP1 interaction ( Fig.”
InfluentialSelf-citationHierarchical Hydrogels with Ordered Micro-Nano Structures for Cancer-on-a-Chip Construction
Zhu, L., Shao, C., Chen, H., Chen, Z., & Zhao, Y. (2021) · Research · doi:10.34133/2021/9845679 · Cited by 41
“In clinical practice, numerous therapeutic methods such as surgical resection, drug therapy, chemotherapy and radiotherapy have been adopted [1-3].”
BackgroundVit, G., Duro, J., Rajendraprasad, G., Hertz, E. P. T., Holland, L. K. K., Weisser, M. B., McEwan, B. C., Lopez‐Mendez, B., Sotelo‐Parrilla, P., Jeyaprakash, A. A., et al. (2022) · The EMBO Journal · doi:10.15252/embj.2022110611 · Cited by 34
SHARPIN S146 phosphorylation mediates ARP2/3 interaction, cancer cell invasion and metastasis
Butt, U., Khan, M. H., Pouwels, J., & Westermarck, J. (2022) · Journal of Cell Science · doi:10.1242/jcs.260627 · Cited by 6
Self-citationOvarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Kaipio, K., Arsiola, T., Laajala, T. D., Connolly, D. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437804 · Cited by 5
Self-citation
Metadata
- Authors
- Vainonen, J. P., Momeny, M., & Westermarck, J.
- Venue
- Science Translational Medicine
- Published
- 2021-04-07
- Volume
- 13
- Issue
- 588
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3140922284
- Cited by
- 104
- References
- 32
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Breast Cancer Now (2017NovPCC1067)
- Foundation of the Finnish Cancer Institute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Druggable cancer phosphatases. https://app.cochat.ai/papers/10.1126/scitranslmed.abe2967
- The paper
- Vainonen, J. P., Momeny, M., & Westermarck, J. (2021). Druggable cancer phosphatases. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abe2967
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.